Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03243799
Other study ID # PI16/01272
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 6, 2017
Est. completion date December 2019

Study information

Verified date May 2019
Source Jordi Gol i Gurina Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary aim is to evaluate the effectiveness of an intervention based on a psychoeducational program carried out by primary care nurses, to improve the rate of remission and response of depression in patients with physical chronic illness (diabetes, COPD, asthma and / or ischemic heart disease). Secondarily, to assess the cost-effectiveness of the intervention, the effectiveness to improve the control of physical pathology, the impact on quality of life and the feasibility of the intervention.

Methods: a multicentre, randomized clinical trial, with two groups and 1 year follow-up evaluation. Economic evaluation study. We will study 504 patients (252 in each group), over 50 years assigned to 25 primary care teams (PC) from Catalonia (urban, semi-urban and rural) with major depression and with at least one of the diseases: diabetes mellitus type 2, chronic obstructive pulmonary disease, asthma, and / or ischemic heart disease. They will be distributed randomly into two groups. The intervention group will participate in psychoeducational groups: 12 weekly 90-minute sessions led by two nurses from PC, consisting of health education on chronic physical illness and depressive symptoms.

Main measurements: clinical remission of depression and / or response to intervention (Beck depression inventory: BDI-II). Secondary measures: improvement in control of chronic disease (blood test and physical parameters), drug compliance (test Morinsky-Green and number of packaging), quality of life (EQ-5D), medical service utilization (appointments and hospital admissions due to complications) and feasibility of the intervention (satisfaction and compliance). Evaluations will be masked and conducted at 0, 3 and 12 months. At 6 months, patients will receive a call from nurses.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 504
Est. completion date December 2019
Est. primary completion date June 2019
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria:

- Presence of at least one of the following diseases: type 2 diabetes mellitus, chronic obstructive pulmonary disease, asthma, and / or ischemic heart disease.

- Meet major depression criteria at the time of the study: Score above 13 on the BDI-II scale.

- Possibility of follow-up of one year by the same primary care team.

- At least read and write Spanish or Catalan.

Exclusion Criteria:

- Diagnosis of dementia or moderate or high cognitive impairment (5 or more errors according to the pfeiffer scale).

- Major depression with psychotic symptoms or with other serious psychiatric comorbidities.

- Moderate or high risk of suicide (6 or more points on the MINI suicide scale).

- Dependency disorders due to alcohol or other drug abuse.

- Advanced stage physical disease.

- Inability to travel to the center.

- Be receiving some psychological therapy by the Center of mental health (CSM) of reference

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Group psychoeducation
Educational group sessions for patients with depression and physical comorbidities in order to improve the degree of control of their illnesses

Locations

Country Name City State
Spain Centre d'Atenció Primària (CAP) Santa Margarida de Montbui Santa Margarida de Montbui Barcelona

Sponsors (2)

Lead Sponsor Collaborator
Jordi Gol i Gurina Foundation Carlos III Health Institute

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in rate of remission of depression Changes in the score of the BDI-II scale At 12 months of follow-up
Secondary Changes in rate of remission of depression Changes in the score of the BDI-II scale At 3 months of follow-up
Secondary Changes in the control of DM2 Changes in HbA1c At 12 months of follow-up
Secondary Changes in the control of COPD Changes in FEV1 At 12 months of follow-up
Secondary Changes in the control of asthma Changes in FEV1 At 12 months of follow-up
Secondary Changes in the control of Ischemic heart disease Changes in LDL cholesterol At 12 months of follow-up
Secondary Referrals to mental health Number of visits to mental health centers At 12 months of follow-up
Secondary Record of therapeutic compliance Morisky-Green test At 12 months of follow-up
Secondary Changes in the quality of life Measured by the EuroQol scale (EQ-5D) At 12 months of follow-up
Secondary Quantification of the use of services Number of hospital admissions At 12 months of follow-up
Secondary Satisfaction with the intervention Survey at the end of the intervention At 3 months of follow-up
Secondary Adherence to the intervention Number of assisted sessions At 3 months of follow-up
Secondary Qualitative changes of the state of mind at the end of the intervention better, equal or worse At 3 and 12 months of follow-up
Secondary Qualitative changes of the state of health at the end of the intervention better, equal or worse At 3 and 12 months of follow-up
See also
  Status Clinical Trial Phase
Completed NCT01316926 - Paxil CR Bioequivalence Study Brazil Phase 1
Recruiting NCT06187454 - Transcranial Direct Current Stimulation for Depression N/A
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Recruiting NCT05768126 - Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine Phase 4
Completed NCT03219879 - Telephone-administered Relapse Prevention for Depression N/A
Recruiting NCT06038721 - Unified Protocol: Community Connections N/A
Completed NCT03043560 - Study to Treat Major Depressive Disorder With a New Medication Phase 2
Completed NCT04091139 - Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong Phase 2/Phase 3
Completed NCT00069459 - Seasonal Affective Depression (SAD) Study Phase 1
Recruiting NCT05503966 - Combining Antidepressants and Attention Bias Modification in Depression N/A
Recruiting NCT03001245 - Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents N/A
Completed NCT02939560 - TMS for Adults With Autism and Depression N/A
Completed NCT02452892 - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) N/A
Completed NCT02542891 - European Comparative Effectiveness Research on Internet-based Depression Treatment N/A
Withdrawn NCT02238730 - Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy N/A
Completed NCT02224508 - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks N/A
Completed NCT02306551 - Well Being And Resilience: Mechanisms of Transmission of Health and Risk
Completed NCT01597661 - Bupropion & Cardio Birth Defect (Slone) N/A
Completed NCT01407575 - Buprenorphine for Treatment Resistant Depression Phase 3
Completed NCT01093053 - Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations N/A